News Biogen Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
202.5 ^USD	+0.23%		+6.27%	-21.76%

Apr. 25	Goldman Sachs Adjusts Biogen Price Target to $340 From $393	MT
Apr. 25	Canaccord Genuity Adjusts Price Target on Biogen to $308 From $305	MT

Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®	Apr. 25	GL
Goldman Sachs Adjusts Biogen Price Target to $340 From $393	Apr. 25	MT
Canaccord Genuity Adjusts Price Target on Biogen to $308 From $305	Apr. 25	MT
Barclays Adjusts Price Target on Biogen to $200 From $215	Apr. 25	MT
HC Wainwright Adjusts Biogen's Price Target to $300 From $325	Apr. 25	MT
Wedbush Adjusts Price Target on Biogen to $215 From $213	Apr. 25	MT
Health Care Down Amid Mixed Earnings -- Health Care Roundup	Apr. 24	DJ
Sector Update: Health Care Stocks Slipping Late Afternoon	Apr. 24	MT
News Highlights : Top Company News of the Day - Wednesday at 3 PM ET	Apr. 24	DJ
Wall St edges lower as rising yields overshadow upbeat corporate results	Apr. 24	RE
Morgan Stanley Cuts Biogen's Price Target to $331 From $339	Apr. 24	MT
Sector Update: Health Care Stocks Softer Wednesday Afternoon	Apr. 24	MT
Sector Update: Health Care	Apr. 24	MT
Piper Sandler Raises Biogen's Price Target to $335 From $325	Apr. 24	MT
RBC Lowers Biogen's Price Target to $317 From $326	Apr. 24	MT
News Highlights : Top Company News of the Day - Wednesday at 1 PM ET	Apr. 24	DJ
News Highlights : Top Company News of the Day - Wednesday at 11 AM ET	Apr. 24	DJ
Biogen Affirms Guidance After Mixed First Quarter	Apr. 24	MT
Nasdaq outshines Wall St peers on tech boost, earnings glee	Apr. 24	RE
News Highlights : Top Company News of the Day - Wednesday at 9 AM ET	Apr. 24	DJ

No results for this search